Alan Frazier


Alan founded Frazier Healthcare Partners in 1991 and has led the firm in raising 11 institutional funds and managing nearly $4.2 billion in assets. During his 27 years as Managing Partner and Chairman, he has worked with entrepreneurs to build many leading healthcare companies, including Array BioPharma (NASDAQ: ARRY), Tularik (acquired by Amgen), Rigel (NASDAQ: RIGL), CV Therapeutics (acquired by Gilead), VIVUS (NASDAQ: VVUS), Corixa (acquired by GSK), Cadence Pharmaceuticals (acquired by Mallinckrodt), TridentUSA (acquired by Formation Capital), Packaging Coordinators, Inc. (acquired by The Partners Group) and most recently, Abode Healthcare (acquired by Tailwind). He currently sits on the board of Orthotic Holdings.

Prior to founding Frazier, he was integrally involved in growing several successful healthcare companies into national prominence. Alan served as Executive Vice President and Chief Financial Officer of Immunex Corporation, an early biotechnology company that discovered and developed the blockbuster drug Enbrel to treat rheumatoid arthritis and other autoimmune disorders. Later, he served as the Senior Financial Advisor and Chief Financial Officer of Affymax and worked on the spin-out of Affymetrix. Prior to Immunex, he was head of the Emerging Business Practice and co-head of the Technology Practice for the Seattle office of Arthur Young & Company (now, Ernst & Young). Alan also previously served on the Fred Hutchinson Cancer Center board as well as the UW Medicine Board and UW Medicine Strategic Initiatives Committee, both affiliated with the University of Washington School of Medicine.


University of Washington (B.A.)

Year Joined